NICE u-turn sees Akcea’s Waylivra win NHS funding
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Read More
Tag: Akcea
Final NICE guidance issued for Akcea’s Tegsedi
The drug should be available for routine use within 90 days for patients in England.
Read More
‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR
The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
Read More
Novartis to licence Akcea’s lipoprotein lowering drug
Novartis has announced that it is exercising its option to license the rights to develop and commercialise Akcea’s TQJ230.
Read More
NICE rejects NHS funding for Tegsedi, Onpattro
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read More
US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
FDA rejects Akcea/Ionis’ rare disease drug Waylivra
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read More
EU approval for Akcea/Ionis’ rare disease therapy
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
FDA advisors back approval of Akcea’s volanesorsen
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read More
Akcea’s rare lipid disorder drug wins PIM status
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
Read More
Novartis taps into Ionis’ cardiovascular drugs
Novartis has signed an exclusive option agreement with Ionis and affiliate Akcea to license two investigational therapies that could significantly reduce cardiovascular risk in patients living with elevated levels of lipoproteins Lp(a) and ApoCIII.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
